The announcement came on the heels of FDA’s clearance for the Pathwork Tissue of Origin test for diagnosis of tumors of uncertain origin, including poorly differentiated, undifferentiated and metastatic tumors.
In addition to offering the Pathwork Tissue of Origin test as a service through the CLIA-certified Pathwork Diagnostics laboratory, FDA clearance of the in vitro diagnostic (IVD) kit version of the test will give Pathwork’s customers the opportunity to purchase an IVD kit and run the test in their own labs.
Abingworth joins the existing investors participating in this round, including Prospect Venture Partners, Advent Venture Partners, Novus Ventures, Venrock and Versant Ventures.
Deborah Neff, president and CEO of Pathwork Diagnostics, said: “With this $20 million round of financing completed and the recent FDA clearance, the company is well positioned to fund important commercialization programs, including offering the Pathwork Tissue of Origin test through an additional distribution channel, and building our pipeline.”